The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys

被引:16
作者
Eberling, JL [1 ]
Pivirotto, P
Bringas, J
Steiner, JP
Kordower, JH
Chu, YP
Emborg, ME
Bankiewicz, KS
机构
[1] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA
[2] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA
[3] Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Funct Imaging, Berkeley, CA 94720 USA
[4] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94103 USA
[5] Guilford Pharmaceut Inc, Baltimore, MD 21224 USA
[6] Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
[7] Rush Presbyterian St Lukes Med Ctr, Res Ctr Brain Repair, Chicago, IL 60612 USA
关键词
GPI-1046; immunophilin; regeneration; MPTP; Parkinson's disease; SPECT; dopamine transporter;
D O I
10.1006/exnr.2002.8023
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Nonimmunosuppressant immunophilin ligands have been shown to have neurotrophic properties in rodent models of Parkinson's disease (PD), although little is known about the effects of these ligands in primates. The immunophilin ligand, GPI-1046, promotes the regeneration of dopamine (DA) cells in association with functional recovery in rodent models. We explored. the regenerative effects of GPI-1046 in an MPTP primate model of PD. We used single photon emission computed tomography,(SPECT) and the DA, transporter tracer (DAT), [I-123]beta-CIT, to evaluate DAT density and clinical recovery before and after treatment with GPI-1046 or vehicle. Subsequent histological studies were also performed. No effects of GPI-1046 were found on any of these measures. These findings show that GPI-1046 does not have regenerative effects in MPTP-treated primates and suggest that there may be species differences with respect to the trophic effects of GPI-1046 on nigrostriatal DA neurons. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:236 / 242
页数:7
相关论文
共 26 条
[1]  
BLOOM FE, 1997, PROGR NEUROINFORMATI, V1, P83
[2]  
Cavalieri B., 1966, GEOMETRIA INDIVISIBL
[3]   A CONSIDERATION OF NEURAL COUNTING METHODS [J].
COGGESHALL, RE .
TRENDS IN NEUROSCIENCES, 1992, 15 (01) :9-13
[4]   Dopamine transporter loss and clinical changes in MPTP-lesioned primates [J].
Eberling, JL ;
Bankiewicz, KS ;
Pivirotto, P ;
Bringas, J ;
Chen, K ;
Nowotnik, DP ;
Steiner, JP ;
Budinger, TF ;
Jagust, WJ .
BRAIN RESEARCH, 1999, 832 (1-2) :184-187
[5]   A novel MPTP primate model of Parkinson's disease: Neurochemical and clinical changes [J].
Eberling, JL ;
Jagust, WJ ;
Taylor, S ;
Bringas, J ;
Pivirotto, P ;
VanBrocklin, HF ;
Bankiewicz, KS .
BRAIN RESEARCH, 1998, 805 (1-2) :259-262
[6]   Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys [J].
Emborg, ME ;
Shin, P ;
Roitberg, B ;
Sramek, JG ;
Chu, Y ;
Stebbins, GT ;
Hamilton, JS ;
Suzdak, PD ;
Steiner, JP ;
Kordower, JH .
EXPERIMENTAL NEUROLOGY, 2001, 168 (01) :171-182
[7]  
Emborg ME, 1998, J COMP NEUROL, V401, P253
[8]   THE NEW STEREOLOGICAL TOOLS - DISECTOR, FRACTIONATOR, NUCLEATOR AND POINT SAMPLED INTERCEPTS AND THEIR USE IN PATHOLOGICAL RESEARCH AND DIAGNOSIS [J].
GUNDERSEN, HJG ;
BAGGER, P ;
BENDTSEN, TF ;
EVANS, SM ;
KORBO, L ;
MARCUSSEN, N ;
MOLLER, A ;
NIELSEN, K ;
NYENGAARD, JR ;
PAKKENBERG, B ;
SORENSEN, FB ;
VESTERBY, A ;
WEST, MJ .
APMIS, 1988, 96 (10) :857-881
[9]   Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo [J].
Harper, S ;
Bilsland, J ;
Young, L ;
Bristow, L ;
Boyce, S ;
Mason, G ;
Rigby, M ;
Hewson, L ;
Smith, D ;
O'Donnell, R ;
O'Connor, D ;
Hill, RG ;
Evans, D ;
Swain, C ;
Williams, B ;
Hefti, F .
NEUROSCIENCE, 1999, 88 (01) :257-267
[10]   SEVERE DEPLETION OF COCAINE RECOGNITION SITES ASSOCIATED WITH THE DOPAMINE TRANSPORTER IN PARKINSONS-DISEASED STRIATUM [J].
KAUFMAN, MJ ;
MADRAS, BK .
SYNAPSE, 1991, 9 (01) :43-49